Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access Venetoclax + Low-Dose Cytarabine in Treatment-Naive AML Ineligible for Intensive Therapy (Japan)
jRCT2080225347Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by AbbVie Inc. Primary endpoint: Safety and tolerability of venetoclax + low-dose cytarabine. Started Aug 2020; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080225347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225347.